Loading…
Immuneering Corporation is projected to rise to $4.47 by 2027, a +8% move from its current price of $4.13. IMRX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/2/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 3 | $3.99 | $4.13 | $4.27 | 0.00% |
| Aug 4 | $3.94 | $4.13 | $4.33 | -0.01% |
| Aug 5 | $3.89 | $4.13 | $4.38 | -0.01% |
| Aug 6 | $3.86 | $4.13 | $4.42 | -0.01% |
| Aug 7 | $3.83 | $4.13 | $4.45 | -0.01% |
| Aug 8 | $3.80 | $4.13 | $4.49 | -0.02% |
| Aug 9 | $3.77 | $4.13 | $4.52 | -0.02% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.77 | $4.13 | $4.52 | -0.02% |
| Week 2 | $3.64 | $4.13 | $4.69 | -0.04% |
| Week 3 | $3.53 | $4.13 | $4.82 | -0.05% |
| Week 4 | $3.45 | $4.13 | $4.94 | -0.07% |
| Week 5 | $3.38 | $4.13 | $5.04 | -0.09% |
| Week 6 | $3.31 | $4.13 | $5.14 | -0.11% |
| Week 7 | $3.25 | $4.12 | $5.23 | -0.12% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Immuneering Corporation is a late-stage oncology company focused on developing medicines for broad populations of cancer patients in the United States.
The company is developing IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic cancer and non-small cell lung cancer caused by mutations of RAS or RAF. IMM-6-415 (envometinib) is in Phase 1/2a trials for the treatment of patients with solid tumors. Immuneering has clinical supply agreements with Regeneron Pharmaceuticals to evaluate atebimetinib in combination with Libtayo in patients with unresectable or metastatic RAS-mutant non-small cell lung cancer; and with Eli Lilly and Company to evaluate atebimetinib in combination with olomorasib in patients with advanced or metastatic KRAS G12C-mutant non-small cell lung cancer.
Immuneering was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
Immuneering Corporation (IMRX) is currently priced at $4.29 per share, with a market capitalization of $277.55M, and ranks 3352.
The year-by-year forecast shows the average price rising from $4.29 in 2026 to $37.29 in 2050, with notable increases in 2030 ($6.57) and 2040 ($16.42).
Near-term sentiment remains NEUTRAL, while the longer-term view turns BULLISH from 2028 onward. These are projections and not guarantees.
A major floor 25.0% below — a decisive break under it would weaken the trend.
Price is testing support right now (1.8% away) — a key level to hold.
The nearest ceiling, 33.9% above — a clean break opens room to run.
A major ceiling 48.4% above — clearing it would confirm fresh momentum.
Key IMRX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of IMRX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $4.20 | Sell | $4.21 | Sell |
| MA 10 | $4.29 | Sell | $4.34 | Sell |
| MA 20 | $4.71 | Sell | $4.51 | Sell |
| MA 50 | $4.67 | Sell | $4.72 | Sell |
| MA 100 | $5.00 | Sell | $4.92 | Sell |
| MA 200 | $5.43 | Sell | $4.95 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 37.87 | Neutral |
| Stoch RSI (14) | 15.90 | Buy |
| CCI (20) | -91.78 | Neutral |
| Williams %R (14) | -93.51 | Info |
| MACD (12,26,9) | -0.07 | Sell |
| ROC (12) | -19.96 | Sell |
| Bollinger %B (20,2) | 0.18 | Neutral |
| Stochastic %K (14) | 6.49 | Buy |
| TRIX (15) | -0.28 | Sell |
| Awesome (5,34) | -0.46 | Sell |
| Ultimate (7,14,28) | 29.16 | Buy |
| Momentum (10) | -0.51 | Sell |
| Aroon Osc (25) | -60.00 | Sell |
| Hull MA (9) | 4.09 | Buy |
| ADX (14) | 18.92 | Neutral |
| ATR (14) | 0.14 | Info |
The 30-day technical picture is NEUTRAL. RSI14: 40, SMA50: $4.83, SMA200: $5.51. Support is $3.92 and resistance is $5.53. The 30-day range runs from a low of $3.31 to a high of $5.57, and annualized volatility is 80%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.92 | $4.13 | $5.55 | 0% | Neutral | |
| $3.49 | $4.47 | $6.11 | +8% | Neutral | |
| $3.97 | $5.27 | $7.53 | +28% | Bullish | |
| $4.03 | $5.52 | $8.17 | +34% | Bullish | |
| $4.71 | $6.62 | $10.08 | +60% | Bullish | |
| $6.03 | $8.68 | $13.57 | +110% | Bullish | |
| $6.30 | $9.29 | $14.85 | +125% | Bullish | |
| $6.34 | $9.55 | $15.57 | +131% | Bullish | |
| $6.30 | $9.68 | $16.09 | +134% | Bullish | |
| $6.52 | $10.22 | $17.27 | +147% | Bullish | |
| $9.73 | $16.69 | $30.33 | +304% | Bullish | |
| $19.06 | $38.40 | $77.36 | +830% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $3.92 | $4.13 | $5.17 | +0.00% |
| September 2026 | $3.53 | $4.21 | $5.17 | +1.84% |
| October 2026 | $3.43 | $4.12 | $5.13 | -2.03% |
| November 2026 | $3.52 | $4.26 | $5.37 | +3.43% |
| December 2026 | $3.59 | $4.37 | $5.55 | +2.49% |
Click any year to see its month-by-month IMRX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, IMRX is projected to trade between $3.92 and $5.55, averaging $4.13 — a potential gain of 0% from today's $4.13. A consolidation phase looks the most probable path here.
Immuneering Corporation's 2027 outlook centres on $4.47, within a $3.49 to $6.11 range. That is up +8% on the projected 2026 average. That marks a +8% change versus current levels. Price action looks broadly range-bound.
By 2028, IMRX could reach as high as $7.53, with a base case around $5.27 and support toward $3.97 — roughly +28% from $4.13. Buyers look set to stay in control over this stretch.
Expect IMRX to range from $4.03 to $8.17 through 2029. The $5.52 average target implies a +34% move from current prices. That is up +5% on the projected 2028 average. Momentum favours further upside here.
The IMRX price prediction for 2030 points to an average of $6.62 (low $4.71, high $10.08) — a potential gain of +60% on today's $4.13. Buyers look set to stay in control over this stretch.
In 2031, IMRX is projected to trade between $6.03 and $13.57, averaging $8.68 — a potential gain of +110% from today's $4.13. That is up +31% on the projected 2030 average. Momentum favours further upside here.
Immuneering Corporation's 2032 outlook centres on $9.29, within a $6.30 to $14.85 range. That is up +7% on the projected 2031 average. That marks a +125% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, IMRX could reach as high as $15.57, with a base case around $9.55 and support toward $6.34 — roughly +131% from $4.13. Momentum favours further upside here.
Expect IMRX to range from $6.30 to $16.09 through 2034. The $9.68 average target implies a +134% move from current prices. That is up +1% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The IMRX price prediction for 2035 points to an average of $10.22 (low $6.52, high $17.27) — a potential gain of +147% on today's $4.13. Momentum favours further upside here.
In 2040, IMRX is projected to trade between $9.73 and $30.33, averaging $16.69 — a potential gain of +304% from today's $4.13. That is up +63% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Immuneering Corporation's 2050 outlook centres on $38.40, within a $19.06 to $77.36 range. That is up +130% on the projected 2040 average. That marks a +830% change versus current levels. Momentum favours further upside here.
Investing $1,000 in IMRX today (≈ 242.130751 IMRX) could be worth
$9,298.81
+$8,298.81 (+830%) by 2050 · US Dollar
Based on the average projected IMRX price of $38.4 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in IMRXwould be worth at today's price.
$1,000 invested in IMRX on Jul 31, 2025 (≈ 290.69767 IMRX) would be worth
$1,200.58
+$200.58 (+20.1%) today · 1.20× · US Dollar
Based on a IMRX entry price of $3.44 vs. today's $4.13.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $4.32 | $956.02 | -4.4% |
| 1 month ago | $5.05 | $817.82 | -18.2% |
| 3 months ago | $5.37 | $769.09 | -23.1% |
| 6 months ago | $4.82 | $856.85 | -14.3% |
| 1 year ago | $3.44 | $1,200.58 | +20.1% |
| All time (5.0y) ago | $19.17 | $215.44 | -78.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our IMRX forecast.
Our base-case forecast reaches $8.30 around 2031.
Implied market cap at $8.30: $536.99M
The multi-year forecast shows a clear path to higher averages and upside potential. In 2026 the avg is $4.29 with a 0% ROI and NEUTRAL sentiment, then 2027 avg $4.52 with 5.4% ROI and NEUTRAL sentiment. The forecast turns bullish in 2028 with avg $5.41 and 26.1% ROI, continuing through 2029 (avg $5.38; ROI 25.3%; sentiment BULLISH) and into 2030 (avg $6.57; ROI 53.2%; sentiment BULLISH).
From 2031 to 2035 the avg rises to $9.04, $9.24, $9.38, $9.68 and $9.75, with ROIs of 110.7%, 115.4%, 118.7%, 125.5% and 127.3% respectively, all with BULLISH sentiment.
2040 shows a substantial step higher: avg $16.42 with ROI 282.7% and BULLISH sentiment. By 2050 the avg reaches $37.29, the max is $80.37, and ROI climbs to 769.2% with BULLISH sentiment. These figures are estimates and carry inherent uncertainty.
Tap a question to reveal the answer.
Avg $6.57; min $4.50; max $10.41; ROI 53.2%; sentiment BULLISH.
Forecasts show a path toward higher averages and positive ROI, with sentiment turning BULLISH from 2028 onward. Key anchors: 2026 avg $4.29 (ROI 0%) and 2027 avg $4.52 (ROI 5.4%), followed by stronger upside later.
Yes—the max forecast for 2050 is $80.37; the avg is $37.29 and min is $16.78; ROI 769.2%; sentiment BULLISH.
Current price is $4.29; market cap is $277.55M.
RSI14 is 40; SMA50 is $4.83; SMA200 is $5.51; support is $3.92; resistance is $5.53; the 30-day range is $3.31 to $5.57; annualized volatility is 80%.
Immuneering Corporation Community Discussion
0Share your Immuneering Corporation price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.